Loading clinical trials...
Loading clinical trials...
A 12-month Multicentre, Randomised, Double-blind, Placebo-controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or Without Other Cardiometabolic Risk Factors.
Conditions
Interventions
Rimonabant
Placebo
Locations
1
Spain
Sanofi-Aventis Administrative Office
Barcelona, Spain
Start Date
March 1, 2007
Primary Completion Date
January 1, 2009
Completion Date
January 1, 2009
Last Updated
December 10, 2010
NCT07472881
NCT01143454
NCT07010757
NCT06223555
NCT06989203
NCT07237750
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions